Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Flavia Sunzini, Arianna D’Antonio, Mauro Fatica, Paola Triggianese, Paola Conigliaro, Elisabetta Greco, Alberto Bergamini & Maria Sole Chimenti. (2022) What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?. Expert Opinion on Biological Therapy 22:12, pages 1545-1559.
Read now
Read now
Amy C. Foulkes, Christopher E. M. Griffiths, Hector Chinoy & Richard B. Warren. (2014) Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. Journal of Dermatological Treatment 25:1, pages 61-62.
Read now
Read now
Philip M Laws & Richard B Warren. (2011) Ustekinumab for the treatment of psoriasis. Expert Review of Clinical Immunology 7:2, pages 155-164.
Read now
Read now
Articles from other publishers (41)
Ahmed Safi Vahidy, Faizan Niaz, Samiuddin Tariq, Irtebaat Fatima, Yusra Afzal & Abdulqadir J. Nashwan. (2023) IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials. Clinical Immunology Communications 4, pages 7-22.
Crossref
Crossref
Danpeng Shen, Zhiqiang Wang, Hongwei Wang, Hongyan Zhu, Cuibao Jiang, Fan Xie, Hongpeng Zhang, Qian Lv, Qi Liu, Nianmin Qi & Hao Wang. (2023) Evaluation of preclinical efficacy of human umbilical cord mesenchymal stem cells in ankylosing spondylitis. Frontiers in Immunology 14.
Crossref
Crossref
Vipawee S. Chat, Shelley K. Uppal, Donovan G. Kearns & Jashin J. Wu. (2021) Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. Dermatologic Therapy 34:4.
Crossref
Crossref
Louisa Nitsch, Linda Schneider, Julian Zimmermann & Marcus Müller. (2021) Microglia-Derived Interleukin 23: A Crucial Cytokine in Alzheimer's Disease?. Frontiers in Neurology 12.
Crossref
Crossref
Dennis McGonagle, Abdulla Watad, Kassem Sharif & Charlie Bridgewood. (2021) Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis. Frontiers in Immunology 12.
Crossref
Crossref
Dennis McGonagle, Abdulla Watad, Kassem Sharif & Charlie Bridgewood. (2021) Warum die Hemmung von IL-23 bei ankylosierender Spondylitis nicht wirksam war. Kompass Autoimmun 3:3, pages 100-107.
Crossref
Crossref
Wei Zhu, Xuxia He, Kaiyuan Cheng, Linjie Zhang, Di Chen, Xiao Wang, Guixing Qiu, Xu Cao & Xisheng Weng. (2019) Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Research 7:1.
Crossref
Crossref
Alan Menter, Bruce E. Strober, Daniel H. Kaplan, Dario Kivelevitch, Elizabeth Farley Prater, Benjamin Stoff, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn M.R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Reena N. Rupani, Michael Siegel, Emily B. Wong, Jashin J. Wu, Vidhya Hariharan & Craig A. Elmets. (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 80:4, pages 1029-1072.
Crossref
Crossref
Phuong Anh Pham, Corinna Dressler, Lisa Eisert, Alexander Nast & Ricardo Niklas Werner. (2019) Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. Rheumatology International 39:4, pages 605-618.
Crossref
Crossref
Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip J Mease, Dafna D Gladman, Linda Chen, Elizabeth Kudlacz, Joseph Wu, Joseph C Cappelleri, Thijs Hendrikx & Ming-Ann Hsu. (2019) Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open 5:1, pages e000808.
Crossref
Crossref
Philip Mease, Vibeke Strand & Dafna Gladman. (2018) Functional impairment measurement in psoriatic arthritis: Importance and challenges. Seminars in Arthritis and Rheumatism 48:3, pages 436-448.
Crossref
Crossref
Tim Pickles, Robin Christensen, Lai-Shan Tam, Lee S Simon & Ernest H Choy. (2018) Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. Rheumatology Advances in Practice 2:2.
Crossref
Crossref
Janet Roberts, Darren D O'Rielly & Proton Rahman. (2018) A review of ustekinumab in the treatment of psoriatic arthritis. Immunotherapy 10:5, pages 361-372.
Crossref
Crossref
Jiří Štolfa. (2018) Biological treatment of psoriatic arthritis. Vnitřní lékařství 64:2, pages 127-135.
Crossref
Crossref
Sibel Bakirci Ureyen, Catherine Ivory, Umut Kalyoncu, Jacob Karsh & Sibel Zehra Aydin. (2018) What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials. Rheumatology Advances in Practice 2:1.
Crossref
Crossref
F.M. Ali, A.C. Cueva, J. Vyas, A.A. Atwan, M.S. Salek, A.Y. Finlay & V. Piguet. (2017) A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. British Journal of Dermatology 176:3, pages 577-593.
Crossref
Crossref
Sarah Elyoussfi, Benjamin J. Thomas & Coziana Ciurtin. (2016) Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatology International 36:5, pages 603-612.
Crossref
Crossref
L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha, N Betteridge, J Braun, G Burmester, J D Cañete, N Damjanov, O FitzGerald, E Haglund, P Helliwell, T K Kvien, R Lories, T Luger, M Maccarone, H Marzo-Ortega, D McGonagle, I B McInnes, I Olivieri, K Pavelka, G Schett, J Sieper, F van den Bosch, D J Veale, J Wollenhaupt, A Zink & D van der Heijde. (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases 75:3, pages 499-510.
Crossref
Crossref
Mahta Mortezavi & Christopher Ritchlin. (2015) IL12/IL23 Inhibition in the Treatment of Psoriatic Arthritis. Current Treatment Options in Rheumatology 1:2, pages 197-209.
Crossref
Crossref
Sherry Rohekar, Jon Chan, Shirley M.L. Tse, Nigil Haroon, Vinod Chandran, Louis Bessette, Dianne Mosher, Cathy Flanagan, Kevin J. Keen, Karen Adams, Michael Mallinson, Carter Thorne, Proton Rahman, Dafna D. Gladman & Robert D. Inman. (2015) 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. The Journal of Rheumatology 42:4, pages 665-681.
Crossref
Crossref
Maria L. Acosta Felquer & Enrique R. Soriano. (2015) New treatment paradigms in psoriatic arthritis. Current Opinion in Rheumatology 27:2, pages 99-106.
Crossref
Crossref
Alison M. Gizinski & David A. Fox. 2015. Rheumatology. Rheumatology
518
521
.
Yi Liu, Jian-ping Gong & Wen-fang Li. (2014) Therapeutic Effect and Safety of Ustekinumab for Plaque Psoriasis: A Meta-analysis. Chinese Medical Sciences Journal 29:3, pages 131-138.
Crossref
Crossref
Kate McKeage. (2014) Ustekinumab: A Review of Its Use in Psoriatic Arthritis. Drugs 74:9, pages 1029-1039.
Crossref
Crossref
Ricardo Prado Golmia, Ayk Helena Barbosa Martins & Morton Scheinberg. (2014) When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis. Revista Brasileira de Reumatologia (English Edition) 54:3, pages 247-249.
Crossref
Crossref
Ricardo Prado Golmia, Ayk Helena Barbosa Martins & Morton Scheinberg. (2014) Quando anti‐TNF não obtém sucesso, anti‐IL‐12‐23 é opção alternativa na psoríase e na artrite psoriásica. Revista Brasileira de Reumatologia 54:3, pages 247-249.
Crossref
Crossref
E. Daudén, S. Castañeda, C. Suárez, J. García-Campayo, A.J. Blasco, M.D. Aguilar, C. Ferrándiz, L. Puig & J.L. Sánchez-Carazo. (2013) Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology 27:11, pages 1387-1404.
Crossref
Crossref
Alice Gottlieb & Kirti Narang. (2013) Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Therapeutic Advances in Musculoskeletal Disease 5:5, pages 277-285.
Crossref
Crossref
Vibeke Strand, Georg Schett, ChiaChi Hu & Randall M. Stevens. (2013) Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study. The Journal of Rheumatology 40:7, pages 1158-1165.
Crossref
Crossref
Sueli Carneiro, Valderílio Feijó Azevedo, Rubens Bonfi glioli, Roberto Ranza, Célio Roberto Gonçalves, Mauro Keiserman, Eduardo de Souza Meirelles, Marcelo de Medeiros Pinheiro, Antonio Carlos Ximenes, Wanderley Bernardo & Percival Degrava Sampaio-Barros. (2013) Recomendações sobre diagnóstico e tratamento da artrite psoriásica. Revista Brasileira de Reumatologia 53:3, pages 227-241.
Crossref
Crossref
Sueli Carneiro, Valderílio Feijó Azevedo, Rubens Bonfiglioli, Roberto Ranza, Célio Roberto Gonçalves, Mauro Keiserman, Eduardo de Souza Meirelles, Marcelo de Medeiros Pinheiro, Antonio Carlos Ximenes, Wanderley Bernardo & Percival Degrava Sampaio-Barros. (2013) Recommendations for the management and treatment of psoriatic arthritis. Revista Brasileira de Reumatologia (English Edition) 53:3, pages 227-241.
Crossref
Crossref
Marie-Elise Truchetet, M. Djavad Mossalayi & Katia Boniface. (2013) IL-17 in the Rheumatologist’s Line of Sight. BioMed Research International 2013, pages 1-18.
Crossref
Crossref
Jason J. Emer, Amir Larian & Mark G. Lebwohl. 2013. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy
319
332.e2
.
R. Queiro & D. Ginard. (2012) Ustekinumab en la artritis psoriásica y la enfermedad de Crohn. Actas Dermo-Sifiliográficas 103, pages 65-72.
Crossref
Crossref
Shimon Sakaguchi, Helen Benham, Andrew P Cope & Ranjeny Thomas. (2012) T‐cell receptor signaling and the pathogenesis of autoimmune arthritis: insights from mouse and man. Immunology & Cell Biology 90:3, pages 277-287.
Crossref
Crossref
Segundo González, Ruben Queiro & Javier Ballina. (2012) Actualización en la patogenia de la artritis psoriásica. Reumatología Clínica 8, pages 1-6.
Crossref
Crossref
E. Daudén, S. Castañeda, C. Suárez, J. García-Campayo, A.J. Blasco, M.D. Aguilar, C. Ferrándiz, L. Puig & J.L. Sánchez-Carazo. (2012) Integrated Approach to Comorbidity in Patients With Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 103, pages 1-64.
Crossref
Crossref
E. Daudén, S. Castañeda, C. Suárez, J. García-Campayo, A.J. Blasco, M.D. Aguilar, C. Ferrándiz, L. Puig & J.L. Sánchez-Carazo. (2012) Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermo-Sifiliográficas 103, pages 1-64.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Rheumatology 23:4, pages 406-409.
Crossref
Crossref
Mary L. Stevenson & Orit Markowitz. (2018) Selection of Therapies in Patients with Psoriasis and Psoriatic Arthritis. Psoriasis Forum 17a:2, pages 144-147.
Crossref
Crossref
Thomas Schirrmann, Torsten Meyer, Mark Schütte, André Frenzel & Michael Hust. (2011) Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy. Molecules 16:1, pages 412-426.
Crossref
Crossref